CureDiab will participate in the 7th Global NASH Congress taking place in London, June 24-25th, 2024. On monday (24th), Prof. Juergen Eckel, CEO of CureDiab, will give a presentation entitled “Activation of the GABA-A receptor counteracts hepatic steatosis and fibrosis: A novel first-in-class approach for MASH therapy”. We look forward to inspiring discussions and to contribute to the efforts of developing novel drugs for NASH treatment.
